Riskpilot← Back to searchSign inGet full accessDialiv AB
ABActiveOrg 5592543804Klåvavägen 24Retail sale of books · NACE 4761Est. 20200 employees
Revenue 2025
SEK 3K
+143% vs 2024
EBITDA margin
-965.2%
-1388% vs 2024
Equity ratio
2.9%
Financial strength
Net profit 2025
SEK -30K
-1315% vs 2024
| Revenue | SEK 3K | +143% |
| EBITDA | SEK -30K | -1388% |
| Net profit | SEK -30K | -1315% |
| Total assets | SEK 3K | -89% |
| Equity | SEK 89 | -100% |
| Employees | 0 | — |
Legal name
Dialiv AB
Org number
5592543804
Legal form
Aktiebolag
NACE code
4761 · Retail sale of books
Founded
4 maj 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-09-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Vi avser att starta och driva en mobilapplikation som kommer att verka som en digital plattform för individer med diabetes, övervikt och hjärt-kärlsjukdomar. Initialt kommer vi inte bedriva sjukvård eller ge medicinska råd till användare på mobilapplikationen. Vi avser att samla olika aspekter av diabetesvård såsom träning, kost, mediciner och riskfaktorer.
Address
Klåvavägen 24
Email
weihang.che@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 | 79 | 0 | 1 | 3 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −36 | −42 | −5 | −2 | −30 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −36 | −42 | −5 | −2 | −30 |
| Net financials | — | — | −0 | −0 | 0 |
| Profit before tax | −36 | −42 | −5 | −2 | −30 |
| Tax | −0 | — | — | — | — |
| Net profit | −36 | −42 | −5 | −2 | −30 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 17 | 5 | 40 | 28 | 3 |
| Equity | 12 | −20 | 29 | 27 | 0 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 5 | 24 | 11 | 1 | 3 |
| Total debt | 5 | 24 | 11 | 1 | 3 |
EBITDA margin
-965.2%
This company
15.8%
Market median
-6209% vs market
20212025
Equity ratio
2.9%
This company
38.2%
Market median
-92% vs market
20212025
Return on equity
-33744.9%
This company
18.4%
Market median
-183496% vs market
20212025
Net profit margin
-965.1%
This company
8.1%
Market median
-12015% vs market
20212025
Asset turnover
1.01×
This company
1.12×
Market median
+10% vs market
20212025
Debt / equity
33.71×
This company
0.62×
Market median
-5337% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AR Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Dialiv AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Araz Rawshani | Deputy Chief Executive Officer | 0 companies |
| Emanuel Mats Vincent Dellsén | Deputy Board Member | 0 companies |
| Weihang Chen | Board of Directors | 0 companies |